“2018 was a year of significant growth for our CINV franchise, and we look forward to continued strong performance this year,” said Barry Quart, Pharm.D., President and CEO of Heron. “In pain management, Heron remains committed to making a significant impact on the opioid epidemic through the development and commercialization of innovative non-opioid pain management products. With a PDUFA goal date of April 30, 2019, we look forward to launching HTX-011 in the U.S. later this year, if approved.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.